May 2026 produced three clinical datasets that will reshape how Indian pharma competes, what investors should be modelling, and which commercial franchises face structural headwinds they aren’t pricing in yet.
1. A triple-agonist obesity drug matching bariatric surgery outcomes.
2. A one-time gene edit that permanently silences a cholesterol gene.
3. An oral pill that nearly doubled survival in pancreatic cancer, a disease that has killed patients with near-total predictability.
Listen to this 20-minute podcast episode for more details. The LinkedIn poll from last week showed 86% of this audience hadn’t yet engaged with ‘one and done’ therapies. This episode is the briefing you probably needed.
